Topic: NEW! Combination Pulsed High Dose Dapsone Protocol
Bartenderbonnie
Frequent Contributor (1K+ posts)
Member # 49177
posted
Dr Richard Horowitz, considered one of the world’s BEST Lyme Literate Medical Doctor, has published his NEW Combination Pulsed High Dosed Dapsone protocol!!!
“ This is, to our knowledge, the first effective, short-term oral, generic protocol for treating CLD/PTLDS and associated co-infections, including Bartonella. We found that 8 weeks of DDDCT followed by a 4-day pulse of HDDCT was sufficient to put patients with CLD/PTLDS into long-term remission if they did not have evidence of active co-infections, i.e., Babesia and Bartonella.
Patients who were co-infected with Bartonella were sicker, with more neuropsychiatric symptoms, immune deficiency, and increased autonomic and peripheral neuropathy. They required 8 weeks of DDDCT followed by a 6-7-day pulse of HDDDCT to improve and/or go into full remission. The 4-day HDDCT, although helpful in relieving symptoms in those with CLD and Bartonella, was insufficient to keep most co-infected patients with Bartonella in remission.
Patients with evidence of chronic Bartonella had superior results using 8 weeks of DDDCT followed by a 6-7-day pulse of HDDCT.
This confirms the culture results from Johns Hopkins researchers looking at Bartonella persisters in culture, where 6 days of combination antibiotic therapy (rifampin, azithromycin, and methylene blue) were required to completely eliminate Bartonella persisters in biofilms [101].
We did not have a 100% success rate using 6 days of Plaquenil, a tetracycline (doxycycline or minocycline), rifampin, azithromycin, pyrazinamide, and dapsone with a higher dose of methylene blue; however, we had superior response rates in the general improvement of symptoms (100%) compared to past dapsone protocols [51,102,103,104, 105]
. Earlier protocols used 8 weeks of DDDCT with shorter courses of high-dose dapsone (4-day maximum) and lower doses of methylene blue. Higher methylene blue dosage as well as extending the length of time on high-dose dapsone (200 mg PO BID) from 4 days to 6-7 days improved response and remission rates, especially in those co-infected with Bartonella.
Pyrazinamide may also have been helpful in inducing remission rates for Bartonella; however, larger controlled studies will be necessary to determine its beneficial effect [325,326]
. Of 23 patients who completed a full 8-week course of DDDCT prior to one or several courses of HDDCT, 7/23 (30.5%) had a full resolution of their Lyme and tick-borne symptoms for 3 months or longer, even if there was prior evidence of co-infections, including Babesia and/or Bartonella.
Three patients (13%) also had a full resolution of their Lyme and tick-borne symptoms for 1 ½ months or longer, having recently completed the full protocol 6 weeks prior, and age, length of illness, or gender did not affect remission rates or clinical improvement.
Sixteen patients (64%) were sick for 10-20 years or longer, and 8/16 (50% were in remission, with 8/16 (50%) showing significant clinical improvement.
We recognize that the tick-borne protocol presented here is complex, has potential gastrointestinal issues (nausea and vomiting) and hematological side effects with HDDCT, and requires a highly motivated health provider and a highly engaged patient.
It is, however, a protocol that we have demonstrated to be safe and effective when patients follow the guidelines outlined in Table 1, Table 2 and Table 3 and Protocols 1 and 2.
Our study brings hope to the Lyme community since this short-term, oral, generic antibiotic protocol can greatly improve and/or completely resolve symptoms in those who are ill, even for decades.
It was ultimately chronic Babesia spp. that played a major role in interfering with the success of DDDCT and HDDCT, and if questions 1 and 22 on the HMQ Lyme questionnaire are positive [194], it should alert the clinician to the possible presence of Babesiosis.
NONE OF THE SIX PATIENTS WHO WERE BABESIA FISH-POSITIVE REMAINED IN LONG TERM REMISSION!
It is essential that we invest more research funding into finding effective treatments for chronic babesia. Patients who are immunosuppressed, splenectomized, and/or elderly with chronic health conditions, including cardiac and pulmonary problems, are at greater risk for lethal complications from Babesia [333].
Since Babesia microti is now resistant to standard anti-malarial therapies, with new species on the horizon, we need new tools and arsenals to fight these chronic parasitic infections, which are making chronic LD patients sicker.”
THANK YOU DR HOROWITZ 💚
Posts: 2977 | From Florida | Registered: Nov 2016
| IP: Logged |
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic